Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Preferred Stock Liabilities (2017 - 2025)

Historic Preferred Stock Liabilities for Northwest Biotherapeutics (NWBO) over the last 11 years, with Q3 2025 value amounting to $13.4 million.

  • Northwest Biotherapeutics' Preferred Stock Liabilities fell 1560.12% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 1560.12%. This contributed to the annual value of $15.5 million for FY2024, which is 1715.46% down from last year.
  • Northwest Biotherapeutics' Preferred Stock Liabilities amounted to $13.4 million in Q3 2025, which was down 1560.12% from $13.8 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Preferred Stock Liabilities high stood at $27.7 million for Q3 2023, and its period low was $13.4 million during Q3 2025.
  • In the last 4 years, Northwest Biotherapeutics' Preferred Stock Liabilities had a median value of $18.7 million in 2023 and averaged $18.8 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' Preferred Stock Liabilities skyrocketed by 10126.58% in 2023 and then tumbled by 4261.19% in 2024.
  • Over the past 4 years, Northwest Biotherapeutics' Preferred Stock Liabilities (Quarter) stood at $23.1 million in 2022, then decreased by 18.83% to $18.7 million in 2023, then decreased by 17.15% to $15.5 million in 2024, then dropped by 13.59% to $13.4 million in 2025.
  • Its last three reported values are $13.4 million in Q3 2025, $13.8 million for Q2 2025, and $14.6 million during Q1 2025.